Kamahda earned $ 1.6 million in the fourth quarter of 202 compared to a profit of $ 5.4 million in the same period last year. The decrease in profit is due to an increase in operating expenses and a decrease in revenues. Total revenue totaled $ 31.5 million in the fourth quarter of 2020, down 2% from $ 32.1 million recorded in the fourth quarter of 2019.
If you want to specialize in the capital market and have a big head and motivation, you can suit us.
The job can be part-time; Flexibility in working hours; Work from home too
Priority (optional) for writing experience and basic knowledge of the capital market.
Leave details and we will get back to you
Thank you for leaving details, we will try to get back to you soon
Stock
Kamhada
-3.41%
Base:2,637
opening:2,656
High:2,674
low:2,500
change:6,403,210
Page Quote News Graphs Company Profile Recommendations
More articles on the subject:
Traded down 2.3% before entering a trading halt. Stock
Kamahda (US)
+ 6.19%
closure:0
opening:8
High:8.16
low:7.9
cycle:–
Page Quote News Graphs Company Profile Recommendations
More articles on the subject:
Decreases 2.7%.
Total revenue in 2020 was $ 133.2 million, according to the revenue forecast the company gave; Adjusted EBITDA in 2020 was $ 25.1 million. Kamahda entered the US plasma collection market through the acquisition of an active and FDA approved plasma collection center, this acquisition promotes the company’s strategy to become a unique and unique plasma products company focused on expanding its antibody preparation portfolio. The acquisition of the company increased expenses and offset the decrease in expenses arising from the corona period.
The company predicts a continued decrease in total and profitable revenues in 2021. At the same time, the company wishes to emphasize that it is focusing on expanding its existing growth engines, which include: Continued growth in the market share of the anti-rabies antibody preparation (KedRAb) in the United States. New International.
Royalties are expected from Galicia sales in the U.S. estimated at between $ 10 million and $ 20 million per year, starting in 2022.
Launch of a portfolio of nine biosimilar products for distribution in Israel between 2022 and 2025, following regulatory approval, and the maximum total revenue from their sale is expected to be between $ 25 million and $ 35 million.
Utilizing the manufacturing facility and the company’s experience in providing manufacturing services for unique antibody preparations, including an FDA-approved antibody preparation marketed in the US which is expected to add about $ 8 million to $ 10 million to Kamhada’s annual revenue, starting in 2023.
The Israeli Ministry of Health has begun treatment of hospitalized corona patients using Kamahada’s plasma-based experimental antibody preparation (IgG), which is given mainly as part of a multicenter clinical trial led by the ministry; The current supply volume of the drug is expected to be sufficient to treat about 500 patients.
Amir London“We are pleased with our ability to address the operational challenges posed by the global corona epidemic and our ability to meet our key 2020 financial targets,” said Amir London, CEO of KamaDa. “Total revenue in 2020 amounted to $ 133.2 million, in line with our annual forecast which was between $ 132 million and $ 137 million. Revenue in 2020 represents a 5% increase over revenue in 2019. These results are a result of the company’s core strengths.” .
Comments on the article(0):
Your response has been received and will be published subject to system policies.
Thanks.
For a new response
Your response was not sent due to a communication problem, please try again.
Return to comment